Literature DB >> 10378860

Outcome after pulmonary thromboendarterectomy.

C J Archibald1, W R Auger, P F Fedullo.   

Abstract

Pulmonary thromboendarterectomy (PTE) surgery is an effective treatment for the majority of patients with chronic thromboembolic pulmonary hypertension (CTEPH), with an acceptable mortality rate. The immediate outcome after PTE has repeatedly shown a dramatic decline in pulmonary vascular resistance, echocardiographic evidence of reduced right heart pressure, and increased perfusion on lung scan. Prospective long-term follow-up studies (1 to 4 years post-PTE) have found most patients to be in New York Heart Association class I or II, with significantly improved quality of life and ability to walk, climb stairs, return to work, and perform household tasks. Disease-related symptoms and hospitalizations and/or emergency room visits have also been significantly reduced. These findings indicate an improved functional status and longer life expectancy can be achieved after PTE.

Entities:  

Mesh:

Year:  1999        PMID: 10378860     DOI: 10.1016/s1043-0679(99)70009-2

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  3 in total

1.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 2.  Surgical Management of Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Andrew M Vekstein; Joseph R Nellis; Sharon L McCartney; John C Haney
Journal:  Cardiol Clin       Date:  2022-02       Impact factor: 2.213

Review 3.  Pulmonary hypertension: work in progress.

Authors:  Paul D Boyce; Aaron B Waxman
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.